RespireRx collaborates with University College London to study treatment options for GRIA disorders
News release
by
RespireRx Pharmaceuticals
New York
|
April 21, 2023 10:52 AM Eastern Daylight Time
RespireRx Pharmaceuticals chief scientific officer Arnold Lippa joins Proactive's Natalie Stoberman to share details of the company's latest collaboration with University College London to study the use of AMPAkines for the treatment of GRIA disorders.
GRIA Disorder refers to a family of rare genetic diseases caused by mutations in the AMPA glutamate receptor genes that cause either a loss or gain in the functioning of these receptors, which are the site of action of RespireRx’s AMPAkines and which play an important role in learning and memory as well as other critical biological functions.
Contact Details
Proactive Investors
+1 347-449-0879
